Navigation Links
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Date:12/9/2008

REDWOOD CITY, Calif., Dec. 9 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery. The primary endpoint evaluated pain intensity (Sum of the Pain Intensity Difference - SPID12) over the 12-hour study period compared to baseline. Results demonstrated that compared to placebo, patients receiving 15 mcg of ARX-01 experienced a statistically significant reduction in pain intensity over the study period, based on the worst observation carried forward imputation method (WOCF), p=0.015. Additionally, at the 15 mcg dose, the study met an important secondary endpoint compared to placebo, the percentage of patient dropouts due to inadequate analgesia, p=0.006. Further, no serious or unexpected adverse events related to ARX-01 were reported in the study.

ARX-01 is a sublingual formulation of the opioid pain medication, sufentanil. ARX-01 is based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.

"We chose a very painful surgery in an elderly patient population to showcase the efficacy and safety of Sublingual Sufentanil NanoTabs in treating acute post-operative pain," said Pamela Palmer, M.D., Ph.D., chief medical officer of AcelRx Pharmaceuticals. "The superior attributes of both the drug and the dosage form enabled these highly encouraging Phase 2 results."

This multicenter, double-blind, randomized, placebo-controlled, dose-finding Phase 2 study evaluated the safety and efficacy of ARX-01 in patients undergoing elective unilateral knee replacement surgery. In the study, 101 patients were randomized to receive either placebo or one of three different dosage strengths of ARX-01: 5mcg, 10m
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Oven Industries Inc. announces ... 5R6-900 temperature controller has many user-friendly benefits. Contained all ... the wall as a self-contained temperature control ... detail makes the device unique, as well as highly ... also be used universally, which allows the user to ...
(Date:5/17/2013)... UK (PRWEB) May 17, 2013 The ... Photonics21 at the association’s recent annual meeting ... including EC Vice-President Neelie Kroes, who called the action ... sectors, and a stimulant to European innovation.” , The ... structure of the new Photonics PPP at its 29 ...
(Date:5/17/2013)... -- Yongye International, Inc. (NASDAQ: YONG ) ("Yongye" ... of crop nutrient products in the People,s ... May 16, 2013, the special committee (the "Special Committee") ... was provided a letter (the "Letter") issued by Abax ... ("Abax") to Full Alliance International Limited ("Full Alliance"). The ...
(Date:5/17/2013)... The paradigm of ‘one drug, one target’ has ... predict the adverse and therapeutic effects of a drug. ... Biology at the Genomics Laboratory, Covance, will discuss the ... when used as part of the QC process. Additionally, ... to identify key clinical targets even in complex data ...
Breaking Biology Technology:New Temperature Control Products Announced by Oven Industries Inc. 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... the world,s leading,online bioscience job board and life ... Career Fair in Chicago, IL on Tuesday April ... Chicago Marriott Oak Brook from 11 am to ... Midwest life science professionals from states like ...
... Do You Have the Guts?, aims to reach five ... Quest Diagnostics,Incorporated (NYSE: DGX ), the nation,s ... the launch of a novel,campaign designed to help increase ... Challenge Colon Cancer: Do You Have,the Guts?," the campaign ...
... of elderly patients could cut their total,mortality by a ... third,according to a new study presented today at the ... the New England,Journal of Medicine., LONDON, March 31 ... (HYVET), which is co-ordinated by scientists from,Imperial College London, ...
Cached Biology Technology:Chicago Biotech Career Fair to Draw Hundreds of Bioscience Candidates and Top Employers 2Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 2Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 3Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 4Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 2Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 4
(Date:5/17/2013)... finds human-caused climate change may have little impact ... host of recent studies that predict their widespread ... findings, which appear in the journal Global ... of a creature thought to be doomed: ... animals, especially forest lizards, will be hard hit ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... Developmental Biology (SDB) 72nd Annual Meeting in Cancun, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
(Date:5/16/2013)... BOSTON The endothelium, the cellular layer lining ... just a few hundred nanometers in thickness, this ... stretch and tissue compression to create a unique ... necessary to partition tissues from the body,s circulatory ... when the barrier must be physically breached ...
Breaking Biology News(10 mins):Climate change may have little impact on tropical lizards 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... food preferences so that they eat less high fat ... at Imperial College London. The findings, published in the ... , suggest a new mechanism by which some types ... A growing number of obese patients are choosing to ...
... gastric bypass, the most common type of bariatric surgery ... effective therapy for morbid obesity. Patients who undergo this ... small pouch and connected to the middle of the ... the reasons behind this surgery,s success have been unclear. ...
... COLLEGE PARK, Md. "Brain cap" technology being ... turn their thoughts into motion. Associate Professor of Kinesiology ... a non-invasive, sensor-lined cap with neural interface software that ... limbs, motorized wheelchairs and even digital avatars. "We ...
Cached Biology News:Gastric bypass surgery changes food preferences 2Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 2Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 3UMD brain cap technology turns thought into motion 2UMD brain cap technology turns thought into motion 3UMD brain cap technology turns thought into motion 4UMD brain cap technology turns thought into motion 5
... g of lyophilized peptide derived from the ... 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptide was ... Cayman's EP1 receptor polyclonal antibody (Catalog No. ... with this antibody to block protein-antibody complex ...
... 75 x ... recommended for immunohistochemistry of paraffin-embedded sections, ... at one end, markings ... normal procedures, precleaned, ...
Complete cell culture media with cytokines...
HAS1 (C-14)...
Biology Products: